• SPX
  • $5,755.10
  • 0.07 %
  • $3.97
  • DJI
  • $42,229.54
  • 0.35 %
  • $149.16
  • N225
  • $39,277.96
  • 0.87 %
  • $340.42
  • FTSE
  • $8,209.60
  • 0.23 %
  • $18.99
  • IXIC
  • $18,176.38
  • -0.04 %
  • -$6.54
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Stock Price, News & Analysis

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Stock Price, News & Analysis

Currency in USD Disclaimer

$52.74

-$0.81

(-1.51%)

Day's range
$52.14
Day's range
$53.55
50-day range
$32.5
Day's range
$55.7
  • Country: US
  • ISIN: VGG1110E1079
52 wk range
$25.38
Day's range
$62.21
  • CEO: Dr. Vladimir Coric M.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 10.21
  • Piotroski Score 3.00
  • Grade Buy
  • Symbol (BHVN)
  • Company Biohaven Pharmaceutical Holding Company Ltd.
  • Price $52.74
  • Changes Percentage (-1.51%)
  • Change -$0.81
  • Day Low $52.14
  • Day High $53.55
  • Year High $62.21

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/06/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $59.00
  • High Stock Price Target $68.00
  • Low Stock Price Target $23.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$6.90
  • Trailing P/E Ratio -4.88
  • Forward P/E Ratio -4.88
  • P/E Growth -4.88
  • Net Income $-408,168,000

Income Statement

Quarterly

Annual

Latest News of BHVN

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.